DAWN O'KEEFE: Open Payments
NPI 1477022135 · FORT COLLINS, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,298 in 43 payments from 10 companies in 2025. Trend: 2023 $100 · 2024 $717 · 2025 $2,298
Food & beverage: $2,082Education: $216
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 8 | $547 |
| Teva Pharmaceuticals USA, Inc. | 6 | $417 |
| Alkermes, Inc. | 6 | $403 |
| Otsuka America Pharmaceutical, Inc. | 12 | $299 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $288 |
| Supernus Pharmaceuticals, Inc. | 1 | $115 |
| E.R. Squibb & Sons, L.L.C. | 2 | $83 |
| Dynavax Technologies Corporation | 1 | $75 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $44 |
| Braeburn Inc. | 1 | $26 |
Products named: INGREZZA, CAPLYTA, ABILIFY ASIMTUFII, ARISTADA, Qelbree, LYBALVI, VIVITROL, UZEDY.
Industry payments across CO — which companies pay providers there.
